MSS51

MSS51 is a mitochondrial protein whose function has diverged sharply between yeast and mammals while retaining a central role in cytochrome c oxidase (CcO) biology (PMID:2177521, PMID:26634192). In yeast, Mss51 is a translational activator of the mitochondrially encoded COX1 mRNA acting through its 5'-UTR, and it concurrently binds newly synthesized, unassembled Cox1 protein in early CcO assembly intermediates—coupling Cox1 synthesis to assembly such that sequestration of Mss51 in these intermediates limits its availability for further translation (PMID:2177521, PMID:19710419). This Cox1-stabilizing complex includes Cox14, Ssc1, and the inner-membrane protein Cox25, with Cox14 required for stable Mss51–Cox1 association and Cox25 bridging the Mss51-containing complex to later assembly steps involving Shy1 and Cox5 (PMID:19710419, PMID:21068384). The mammalian ortholog (ZMYND17) has lost the translational-activator role—its deletion in human cells does not affect mitochondrial translation but reduces CcO activity—and instead localizes to skeletal-muscle mitochondria where it acts as an inhibitor of mitochondrial respiration, β-oxidation, glycolysis, and oxidative phosphorylation (PMID:26634192, PMID:34565318). In vivo, Mss51 loss enhances myofiber oxygen consumption and oxidative gene expression and confers resistance to diet-induced obesity, insulin resistance, and hepatic steatosis, establishing it as a brake on muscle mitochondrial metabolism and whole-body energetics (PMID:29913553, PMID:31527314). Mss51 expression is controlled transcriptionally by YY1, which directly binds its promoter and is repressed by betaine (PMID:39187977), and post-transcriptionally by YTHDF2 binding to MSS51 mRNA (PMID:38830447), and the protein is positioned downstream of TGF-β1/myostatin and Site-1 protease (S1P) signaling that suppresses muscle mitochondrial respiration (PMID:26634192, PMID:37002920).

1. 1990 High

   Established that the yeast Mss51 gene product is a dedicated translational activator of mitochondrial COX1 mRNA rather than a splicing factor, defining its founding molecular role.

   Evidence Genetic analysis of mss51 mutants, with a paromomycin-resistance mutation in 15S mitoribosomal RNA linking Mss51 to the ribosome

   PMID:2177521

   Open questions at the time

   • Did not define the physical partners of Mss51
   • Mechanism of ribosome engagement not resolved
2. 2009 High

   Resolved how Mss51 couples Cox1 synthesis to assembly by showing it both activates COX1 translation and binds newly made Cox1, with Cox14 required to sequester it and limit further translation.

   Evidence Reporter assays at the COX1 locus, co-immunoprecipitation of Mss51 with Cox1 assembly intermediates, and cox14 epistasis in yeast

   PMID:19710419

   Open questions at the time

   • Full subunit composition of the stabilization complex incomplete
   • Stoichiometry and release mechanism unknown
3. 2010 High

   Identified Cox25 as an essential member of the Cox1–Ssc1–Mss51–Cox14 stabilization complex and showed it bridges to later CcO assembly intermediates.

   Evidence Reciprocal Co-IP of Cox25 with Mss51, Ssc1, Cox14, Cox1, plus cox25 genetics and fractionation in yeast

   PMID:21068384

   Open questions at the time

   • Timing of Ssc1–Mss51 release not directly observed
   • Structural arrangement of the complex unresolved
4. 2015 Medium

   Showed the mammalian ortholog acts as a metabolic inhibitor rather than a translational activator, localizing to muscle mitochondria and restraining respiration, β-oxidation, and glycolysis.

   Evidence Subcellular fractionation, CRISPR/Cas9 KO in C2C12 myoblasts with ATP, β-oxidation, glycolysis and OXPHOS assays, and qRT-PCR

   PMID:26634192

   Open questions at the time

   • Molecular mechanism of metabolic inhibition not defined
   • Single lab, two orthogonal methods
   • No direct molecular partners identified in mammals
5. 2018 High

   Established Mss51 as an in vivo regulator of muscle mitochondrial quality whose loss alters mitochondrial morphology and respiration and influences systemic metabolism.

   Evidence Zmynd17 KO mouse with electron microscopy, respiration assays, and metabolic phenotyping under high-fat diet

   PMID:29913553

   Open questions at the time

   • Mechanism linking Mss51 to mitochondrial morphology unclear
   • Direct molecular target unidentified
6. 2019 High

   Confirmed Mss51 as a brake on muscle mitochondrial respiration and whole-body metabolism, and showed exercise- and PGC1α-driven mitochondrial pathways act independently of it.

   Evidence CRISPR KO mice with Seahorse OCR, hyperinsulinemic-euglycemic clamp, high-fat diet challenge, PGC1α overexpression and exercise epistasis

   PMID:31527314 PMID:31921843

   Open questions at the time

   • Biochemical mechanism of respiration suppression unresolved
   • How Mss51 intersects mitochondrial quality control unknown
7. 2021 Medium

   Demonstrated functional divergence of the human ortholog from yeast: its loss does not affect mitochondrial translation but lowers CcO activity and raises free ATP synthase F1.

   Evidence ZMYND17 deletion in human cells with measurement of translation products, CcO activity, and ATP synthase F1 assessment

   PMID:34565318

   Open questions at the time

   • Mechanism linking ZMYND17 to CcO activity unknown
   • Single lab
   • Whether it physically contacts CcO not tested
8. 2024 High

   Defined upstream regulators of mammalian Mss51—transcriptional repression by YY1/betaine and post-transcriptional control by YTHDF2—and confirmed its suppression of mitochondrial respiration in vivo.

   Evidence ChIP/EMSA/luciferase and AAV overexpression in muscle (YY1/betaine); RNA immunoprecipitation and knockdown in PCOS granulosa cells (YTHDF2)

   PMID:38830447 PMID:39187977

   Open questions at the time

   • How these inputs are integrated in vivo unclear
   • Direct effector of Mss51 on respiratory machinery still unidentified
9. 2024 Medium

   Placed mammalian Mss51 downstream of S1P/TGF-β1 signaling controlling muscle mass and respiration.

   Evidence Muscle-specific S1P KO mouse with Mss51 overexpression rescue and respiration assays

   PMID:37002920

   Open questions at the time

   • Direct molecular link between S1P signaling and Mss51 expression not defined
   • Single lab, rescue-based epistasis
10. 2024 Medium

    Refined the yeast translational-activation model by showing Mss51 stably associates with the mitoribosome independently of COX1 mRNA or Pet309, rather than via mRNA-dependent recruitment.

    Evidence Co-sedimentation of Mss51 and Pet309 with mitoribosome plus genetic removal of COX1 mRNA/activators (preprint)

    PMID:bio_10.1101_2024.11.01.621605

    Open questions at the time

    • Preprint, single lab
    • No direct Mss51–COX1 mRNA interaction detected
    • Structural basis of ribosome binding unknown

• The direct molecular effector through which mammalian MSS51/ZMYND17 inhibits mitochondrial respiration and metabolism remains undefined.
• No mammalian physical interactor identified
• No structural model of the divergent mammalian protein
• Mechanistic link between CcO activity change and metabolic phenotype unresolved